1. Curtin BJ. The posterior staphyloma of pathologic myopia. Trans Am Ophthalmol Soc. 1977; 75:67–86.
2. Apple DJ, Rabb MF, Walsh PM. Congenital anomalies of the optic disc. Surv Ophthalmol. 1982; 27:3–41.
Article
3. Tosti G. Serous macular detachment and tilted disc syndrome. Ophthalmology. 1999; 106:1453–1455.
Article
4. Leys AM, Cohen SY. Subretinal leakage in myopic eyes with a posterior staphyloma or tilted disk syndrome. Retina. 2002; 22:659–665.
Article
5. Theodossiadis PG, Grigoropoulos V, Emfietzoglou J, Theodossiadis GP. Optical coherence tomography study of tilted optic disk associated with macular detachment. Graefes Arch Clin Exp Ophthalmol. 2006; 244:122–124.
Article
6. Nakanishi H, Tsujikawa A, Gotoh N, et al. Macular complications on the border of an inferior staphyloma associated with tilted disc syndrome. Retina. 2008; 28:1493–1501.
Article
7. Cohen SY, Quentel G, Guiberteau B, et al. Macular serous retinal detachment caused by subretinal leakage in tilted disc syndrome. Ophthalmology. 1998; 105:1831–1834.
Article
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1432–1444.
Article
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419–1431.
Article
10. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009; 147:94–100.
Article
11. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010; 30:407–412.
12. Milani P, Pece A, Pierro L, et al. Bevacizumab for macular serous neuroretinal detachment in tilted disk syndrome. J Ophthalmol. 2010; 2010:970580.
Article
13. Donati MC, Miele A, Abbruzzese G, et al. Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases. Eur J Ophthalmol. 2013; 23:267–270.
Article
14. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008; 146:496–500.
Article
15. Hirata M, Tsujikawa A, Matsumoto A, et al. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2011; 52:4971–4978.
Article
16. Yamagishi T, Koizumi H, Yamazaki T, Kinoshita S. Choroidal thickness in inferior staphyloma associated with posterior serous retinal detachment. Retina. 2012; 32:1237–1242.
Article
17. Ellabban AA, Tsujikawa A, Matsumoto A, et al. Macular choroidal thickness measured by swept source optical coherence tomography in eyes with inferior posterior staphyloma. Invest Ophthalmol Vis Sci. 2012; 53:7735–7745.
Article
18. Maruko I, Iida T, Sugano Y, et al. Morphologic choroidal and scleral changes at the macula in tilted disc syndrome with staphyloma using optical coherence tomography. Invest Ophthalmol Vis Sci. 2011; 52:8763–8768.
Article
19. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009; 284:21036–21046.
Article
20. Nicoletti VG, Nicoletti R, Ferrara N, et al. Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). Exp Clin Endocrinol Diabetes. 2003; 111:209–214.
Article
21. Saenz-de-Viteri M, Fernandez-Robredo P, Hernandez M, et al. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. Biochem Pharmacol. 2016; 103:129–139.
Article
22. Hirano Y, Yasukawa T, Tsukada A, et al. Resolution of exudative changes refractory to ranibizumab after aflibercept injections at the margin of inferior staphyloma in tilted disc syndrome. Ophthalmic Surg Lasers Imaging Retina. 2015; 46:384–386.
Article